BioSpace News Archive

OncoSec Medical Incorporated (“OncoSec”) (Nasdaq:ONCS), a company developing late-stage intratumoral cancer immunotherapies, today announced it will present a poster highlighting a safety and biomarker analysis on its lead product candidate, TAVO™, at the upcoming Society for Immunotherapy of Cancer (SITC) 34th Annual Meeting being held November 6-10, 2019 in National Harbor, Maryland.

Field Trip Psychedelics Inc. (“Field Trip” or the “Company”), the world’s first integrated company in legal psychedelics and psychedelic-assisted psychotherapy, is pleased to announce the appointment of of Dr. Michael Ehlers as a Strategic Advisor to the Company.

Gamida Cell Ltd. (Nasdaq: GMDA), a leading cellular and immune therapeutics company, today announced that the company will host a conference call and live audio webcast on Wednesday, November 13, 2019, at 4:30 p.m. ET to review its third quarter 2019 financial results and provide an update on the company.

X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of rare diseases, today announced the initiation of a Phase 1b clinical trial of mavorixafor (X4P-001) for the treatment of Severe Congenital Neutropenia (SCN), a group of rare blood disorders characterized by abnormally low levels of neutrophils.

EpicentRx, Inc., a clinical cancer immunotherapy company targeting both sides of the immune system to deliver cancer treatments with minimal toxicity, announced today that it has dosed the first patient in the Phase 3 REPLATINUM trial evaluating RRx-001 for the treatment of third-line and beyond small cell lung cancer (SCLC).

Diality Inc. (diality.com), a medical device company that is redefining home dialysis by developing a smart, flexible and portable home hemodialysis machine, today announced the close of a $10 million Series A investment round.

Ashley Winslow, Ph.D, joins Odylia Therapeutics as Chief Scientific Officer.

Octapharma announced today that the human fibrinogen concentrate fibryga® has received approval for use in treatment of acquired fibrinogen deficiency (AFD) in 15 European countries.

Stereotaxis (NYSE American: STXS) and inHEART today announced the first patients have been successfully treated with the integration of inHEART’s advanced preoperative mapping and Stereotaxis’ Robotic Magnetic Navigation technologies.

Mitsubishi Tanabe Pharma Canada, Inc. (MTP-CA), a subsidiary of Mitsubishi Tanabe Pharma America, Inc. (MTPA), today announced that RADICAVA® (edaravone) is now available in Canada